Our data demonstrated that the anti-PD-L1 IFN fusion protein enhanced tumor antigen specific CD8+ T cell killing in vitro and was effective in an anti-PD-L1 resistant syngeneic mouse tumor model in vivo. Here, CD8A is linked to neoplasm.